Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known Unknowns

Gideon M Blumenthal¹, Marc R Theoret¹, Richard Pazdur^{1

2}

Affiliations

¹ Office of Hematology Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.

Comment

Gideon M Blumenthal et al. JAMA Oncol. 2017.

. 2017 Nov 1;3(11):1473-1474.

doi: 10.1001/jamaoncol.2017.1819.

Gideon M Blumenthal¹, Marc R Theoret¹, Richard Pazdur^{1

2}

¹ Office of Hematology Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Comment on

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD. Long GV, et al. JAMA Oncol. 2017 Nov 1;3(11):1511-1519. doi: 10.1001/jamaoncol.2017.1588. JAMA Oncol. 2017. PMID: 28662232 Free PMC article.